1149 GMT - Sales of GSK's respiratory syncytial virus vaccine Arexvy are expected to peak at $4 billion and could surpass consensus, Jefferies analysts say in a note. However, the company still needs further in-licensing or bolt-on deals to sustain the business after that, they add. "We believe that investors will also be pleased and relieved to see the retained guidance, looking thereafter to the shape and magnitude of ongoing earnings," the analysts say. Credit Suisse rates the stock outperform and has a price target at 1,660 pence. "Today's update builds on the company's previous commentary of an overall robust outlook across U.S. and international [businesses]," the analysts say.

Source: Wall Street Journal May 30, 2023 13:14 UTC